DUBLIN--(BUSINESS WIRE)--The "Anti-Viral Drug Therapy Global Market Report 2020-30: Covid 19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
The global anti-viral drug therapy market is expected to grow from $52.2 billion in 2019 to about $59.9 billion in 2020 as there is a surge in demand for antiretroviral drugs used in the treatment of Covid-19 patients. The market is expected to stabilize and reach $62.6 billion at a CAGR of 4.6% through 2023.
The anti-viral drug therapy market consists of sales of anti-viral drugs used for the treatment of viral infections, such as human immunodeficiency virus (HIV), hepatitis, influenza and novel coronavirus. Antiviral drugs do not kill their target pathogen, instead they inhibit the development of those viruses. The anti-viral drugs establishments are primarily engaged in the manufacturing of DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others.
This report from the publisher covers this critical market and the impact on it from the Covid 19 virus. It provides strategists, marketers and senior management with the critical information they need to assess the increasing demand for anti-viral drugs which play a critical role in the treatment of patients with Covid 19
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
- Understand how the market is experiencing rapid growth due to the coronavirus and how it is likely to stabilize as the impact of the virus abates
- Create regional and country strategies on the basis of local data and analysis
- Identify growth segments for investment
- Outperform competitors using forecast data and the drivers and trends shaping the market
- Understand customers based on the latest market research findings
- Benchmark performance against key competitors
- Utilize the relationships between key data sets for superior strategizing
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order
Major players in the anti-viral drug therapy market are AbbVie Inc., Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Dr. Reddy's Laboratories Ltd, and AstraZeneca plc.
The demand for anti-viral drugs is anticipated to grow at a rapid pace due to the novel coronavirus outbreak. As there are no vaccines and potential treatments for Covid-19, companies are trying to repurpose existing drugs in the fight against the novel coronavirus. The use of certain existing anti-viral drugs for the covid-19 treatment is contributing to the growth of anti-viral drugs market. However, if any of these drugs under trails show further promising results in treating the coronavirus infection, the anti-viral market will see further growth.
North America was the largest region in the anti-viral drug therapy market in 2019. The anti-viral drug therapy market in Asia-Pacific is forecasted to register the highest CAGR during 2019-2023.
The anti-viral drug therapy market covered in this report is segmented by drug class into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, others and by application into HIV, hepatitis, herpes, influenza, others.
In February 2020, GeoVax, a US-based pharmaceutical company, and BravoVax, a China-based pharmaceutical company, have announced plans to develop a coronavirus cure in the form of vaccine based on the former's MVA-VLP vaccine platform. BravoVax will be responsible for testing and manufacturing the vaccine as well as coordinating with the public health and regulatory authorities in China.
Increasing public-private funding for life science research globally is expected to drive the growth of anti-viral drug therapy market . Currently, there are no drugs or vaccines approved for treatment of Covid-19 disease, however, there are several vaccines and drugs in pipeline, and are yet to be approved or launched. Governments around the world announced new grant funds for researchers in vaccines, treatment and diagnostics. Canada government announced C$275M for coronavirus research. Wellcome and the Gates Foundation announced they are joining forces with the credit card company MasterCard in a $125 million push to speed up development of drugs for treating COVID-19 infections. Hence increasing public-private funding for life science research will enhance the research and development which drive the growth of covid-19 anti-viral drug therapy market.
Key Topics Covered:
1. Executive Summary
2. Anti-Viral Drug Therapy Market Characteristics
3. Anti-Viral Drug Therapy Market Size And Growth
3.1. Global Anti-Viral Drug Therapy Market Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Anti-Viral Drug Therapy Market Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market
4. Anti-Viral Drug Therapy Market Segmentation
4.1. Global Anti-Viral Drug Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Anti-Viral Drug Therapy Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Anti-Viral Drug Therapy Market Regional And Country Analysis
5.1. Global Anti-Viral Drug Therapy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Anti-Viral Drug Therapy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
- Philips Healthcare
- Becton, Dickinson and Company
- GE Healthcare
- Hamilton Medical
- Smiths Group
- Fisher & Paykel
- Air Liquide
- Allied Healthcare Products
- Teleflex Incorporated
For more information about this report visit https://www.researchandmarkets.com/r/nppdi2